Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoTRIPaPDL1: Atezolizumab with Carboplatin and Nab-paclitaxel in TNBC
NCT02620280Phase 3Completed
- Sponsor
- Michelangelo Foundation
- Start
- Apr 2016
- Primary completion
- Jan 2024
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 3 trial of atezolizumab in triple-negative breast cancer (TNBC), sponsored by Michelangelo Foundation. Started Apr 2016; status: completed.
02
Drugs
atezolizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02620280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02620280.